Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Inclusion Criteria: * A diagnosis of asthma (according to GINA 2016) for a period of at least 6 months. * Treated with medium dose inhaled corticosteroid (ICS), or high dose ICS, or low dose ICS plus long- acting beta agonist (LABA), or low dose ICS plus leukotriene receptor antagonist (LTRA), or medium dose ICS plus LABA for at least 3 months prior to Visit 1 and the doses have been stable for at least 4 weeks prior to Visit 1. * FEV1 of ≤85% for patients aged ≥18 years. FEV1 of ≤90% for patients aged 12 to \<18 years. * Daytime asthma symptom score (0 to 6 scale) of ≥1 per day during 4 of the last 7 days of the placebo run- in period. * Total daily SABA use ≥1 puff per day during 4 of the last 7 days of the placebo run-in period. * Demonstrated reversible airway obstruction. * Asthma control questionnaire (ACQ) score ≥ 1.5. Exclusion Criteria: * Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer. * A resting QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female). * Pregnant or nursing (lactating) women. * Serious co-morbidities. * Patients on \>20 mg of simvastatin, \> 40 mg of atorvastatin, \>40 mg of pravastatin, or \>2 mg of pitavastatin. Other protocol-defined inclusion/exclusion criteria may apply.